(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 February 2023 (09.02.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/015278 A1

(51) International Patent Classification:
C07K 16/28 (2006.01)

(21) International Application Number:
PCT/US2022/074575

(22) International Filing Date:
05 August 2022 (05.08.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/229,836	05 August 2021 (05.08.2021)	US
63/348,388	02 June 2022 (02.06.2022)	US

(71) Applicant: **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, Indiana 46285 (US).

(72) Inventors: **ATWELL, Shane Krummen**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **FENG, Yiqing**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **KARTA, Maya Rachel**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **LEUNG, Donmienne Doen Mun**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **NA, Songqing**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **PELLETIER, Laura Anne**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **RUIZ, Diana Isabel**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US). **STOKELL, David John**; c/o Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(74) Agent: **PATEL, Dipa** et al.; Eli Lilly And Company, P.O. Box 6288, Indianapolis, Indiana 46206-6288 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: HUMAN INTERLEUKIN-4 RECEPTOR ALPHA ANTIBODIES

(57) Abstract: The present disclosure relates to antibodies that specifically bind human IL-4Rα, compositions comprising such IL-4Rα antibodies, and methods of using such IL-4Rα antibodies.

WO 2023/015278 A1